慢性丙型肝炎儿童抗病毒治疗现状及进展  

Antiviral treatment status and progress of chronic hepatitis C in children

作　　者：朱世殊[1] 董漪[1] 

机构地区：[1]中国人民解放军第三〇二医院青少年肝病诊疗与研究中心,北京100039

出　　处：《中华实用儿科临床杂志》2017年第10期727-729,共3页Chinese Journal of Applied Clinical Pediatrics

摘　　要：慢性丙型肝炎（CHC）患儿丙型肝炎病毒RNA阳性即可考虑开始抗病毒治疗。α干扰素或聚乙二醇α干扰素联合利巴韦林抗病毒治疗取得了较好疗效，但不良反应较多。不良反应可通过与监护人的沟通、必要的护理与治疗可以缓解。一部分小分子化合物已开始在儿童CHC中进行临床试验，初步取得了与成人一样的安全性和疗效。但鉴于儿童这个特殊人群还有很多的研究工作要做。Children with hepatitis C virus RNA positive were considered to start antiviral treatment.Alpha interferon or pegylated interferon plus ribavirin in children achieved satisfactory sustain virology response.Although there were many adverse events, some can be relieved by communicating with the guardian, bringing care to the patient and giving treatment.Clinical trials in children with hepatitis C by the direct-acting antiviral agents were in progress, safety and efficacy have no differences with the adult.There were still lots of work to do in view of the particularity of children.

关 键 词：慢性丙型肝炎 干扰素 利巴韦林 治疗 儿童 

分 类 号：R725.1[医药卫生—儿科]